All lobbying filings

GRIFOLS SHARED SERVICES NORTH AMERICA, INC.

Lobbying for GRIFOLS SHARED SERVICES NORTH AMERICA INC

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · District of Columbia · House · Senate · $450,000.00 expenses · posted Oct 17, 2025

Official filing document

Bills named in this filing 12

HR 1476
PLASMA Act
S 694
PLASMA Act
HR 1143
Medicare IVIG Access Enhancement Act of 2025
HR 2343
John W. Walsh Alpha-1 Home Infusion Act of 2025
HR 2172
Preserving Patient Access to Home Infusion Act
S 1818
Prescription Drug Price Relief Act of 2025
HR 3546
Prescription Drug Price Relief Act of 2025
S 1587
Fair Prescription Drug Prices for Americans Act
HR 3375
Fair Prescription Drug Prices for Americans Act
S 1753
End Price Gouging for Medications Act
HR 3493
Global Fairness in Drug Pricing Act
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

Lobbying activity 4

Health Issues

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 H.R. 2172, Preserving Patient Access to Home Infusion Act S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act H.R. 3493, Global Fairness in Drug Pricing Act Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act; drug price negotiations, Part D rebate

Immigration

Issues related to immigration policy

Budget/Appropriations

FY2026 Appropriations bill for Health and Human Services; Medicare and Medicaid drug pricing and eligibility H.R. 1, One Big, Beautiful Bill Act; Medicare provisions - Most Favored Nations and drug pricing, Medicaid provisions - PBM Reform and eligibility, R&D tax credits

Tariff (miscellaneous tariff bills)

Issues related to tariff policy; tariffs on pharmaceuticals and related products

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.